Amanda K Jan1, Julia V Moore1, Richard J Wang2, Maggie Mcging1, Carly K Farr3, Daniela Moisi4, Marlena Hartman-Filson1, Robert Kerruish3, Diane Jeon1, Eula Lewis5, Kristina Crothers3, Michael M Lederman4, Peter W Hunt6, Laurence Huang1,2. 1. Division of HIV, Infectious Diseases and Global Medicine. 2. Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA. 3. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA. 4. Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH. 5. Department of Anesthesia and Perioperative Care, San Francisco General Hospital. 6. Division of Experimental Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Abstract
OBJECTIVES: Studies have shown that people with HIV (PWH) may be at increased risk for chronic lung diseases and lung function abnormalities, which may be associated with immune activation. We tested the association of a panel of 12 immune activation and inflammation biomarkers with spirometry and single-breath diffusing capacity for carbon monoxide (DLco). DESIGN: Cross-sectional, observational study. METHODS: Participants were enrolled from the Inflammation, Aging, Microbes and Obstructive Lung Disease cohort of PWH at two US sites. Biomarkers were examined and standardized spirometry and DLco testing were performed. We tested associations between each biomarker and lung function, examined individually and in combination, using multi-variable linear and logistic regression. RESULTS: Among 199 participants, median forced expiratory volume in 1 s (FEV1) was normal (90% predicted) and median DLco was abnormal (69% predicted). The most common lung function abnormality (57%) was a normal FEV1 to forced vital capacity ratio with an abnormal DLco of 80% or less predicted (iso↓DLco). Two markers (IL-6, high-sensitivity C-reactive protein) were associated with FEV1% predicted, whereas eight markers (soluble CD14, soluble CD163, inducible protein-10, soluble CD27, IL-6, soluble tumor necrosis factor receptors 1 and 2, D-dimer) were associated with DLco% predicted. Compared with those participants with normal spirometry and DLco, five markers (soluble CD14, soluble CD163, interferon gamma inducible protein-10, soluble tumor necrosis factor receptors 1 and 2) were associated with iso↓DLco. CONCLUSION: Among PWH, different markers of immune activation and inflammation are associated with FEV1% predicted than with DLco% predicted and with an iso↓DLco, representing possible unique pathways of chronic lung disease. Identifying plausible drivers of these inflammatory pathways may clarify mechanisms underlying impaired lung function in HIV infection and may identify therapeutic avenues.
OBJECTIVES: Studies have shown that people with HIV (PWH) may be at increased risk for chronic lung diseases and lung function abnormalities, which may be associated with immune activation. We tested the association of a panel of 12 immune activation and inflammation biomarkers with spirometry and single-breath diffusing capacity for carbon monoxide (DLco). DESIGN: Cross-sectional, observational study. METHODS: Participants were enrolled from the Inflammation, Aging, Microbes and Obstructive Lung Disease cohort of PWH at two US sites. Biomarkers were examined and standardized spirometry and DLco testing were performed. We tested associations between each biomarker and lung function, examined individually and in combination, using multi-variable linear and logistic regression. RESULTS: Among 199 participants, median forced expiratory volume in 1 s (FEV1) was normal (90% predicted) and median DLco was abnormal (69% predicted). The most common lung function abnormality (57%) was a normal FEV1 to forced vital capacity ratio with an abnormal DLco of 80% or less predicted (iso↓DLco). Two markers (IL-6, high-sensitivity C-reactive protein) were associated with FEV1% predicted, whereas eight markers (soluble CD14, soluble CD163, inducible protein-10, soluble CD27, IL-6, soluble tumor necrosis factor receptors 1 and 2, D-dimer) were associated with DLco% predicted. Compared with those participants with normal spirometry and DLco, five markers (soluble CD14, soluble CD163, interferon gamma inducible protein-10, soluble tumor necrosis factor receptors 1 and 2) were associated with iso↓DLco. CONCLUSION: Among PWH, different markers of immune activation and inflammation are associated with FEV1% predicted than with DLco% predicted and with an iso↓DLco, representing possible unique pathways of chronic lung disease. Identifying plausible drivers of these inflammatory pathways may clarify mechanisms underlying impaired lung function in HIV infection and may identify therapeutic avenues.
Authors: A M Morris; L Huang; P Bacchetti; J Turner; P C Hopewell; J M Wallace; P A Kvale; M J Rosen; J Glassroth; L B Reichman; J D Stansell Journal: Am J Respir Crit Care Med Date: 2000-08 Impact factor: 21.405
Authors: Kristina Crothers; Laurence Huang; Joseph L Goulet; Matthew Bidwell Goetz; Sheldon T Brown; Maria C Rodriguez-Barradas; Krisann K Oursler; David Rimland; Cynthia L Gibert; Adeel A Butt; Amy C Justice Journal: Am J Respir Crit Care Med Date: 2010-09-17 Impact factor: 21.405
Authors: Ditte M Kirkegaard-Klitbo; Niels Mejer; Troels B Knudsen; Holger J Møller; Søren K Moestrup; Susanne D Poulsen; Gitte Kronborg; Thomas Benfield Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: M Bradley Drummond; Gregory D Kirk; Jacquie Astemborski; Mariah M Marshall; Shruti H Mehta; John F McDyer; Robert H Brown; Robert A Wise; Christian A Merlo Journal: Thorax Date: 2011-11-16 Impact factor: 9.139
Authors: Amy C Justice; Matthew S Freiberg; Russ Tracy; Lew Kuller; Janet P Tate; Matthew Bidwell Goetz; David A Fiellin; Gary J Vanasse; Adeel A Butt; Maria C Rodriguez-Barradas; Cynthia Gibert; Kris Ann Oursler; Steven G Deeks; Kendall Bryant Journal: Clin Infect Dis Date: 2012-02-15 Impact factor: 9.079
Authors: Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson Journal: Am J Respir Crit Care Med Date: 2019-10-15 Impact factor: 21.405
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Sarath Raju; Jacquie Astemborski; Michael Bradley Drummond; Hema C Ramamurthi; Jing Sun; Robert H Brown; Gregory D Kirk; Meredith C McCormack Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771